This article is more than 5 years old. Information may no longer be current.
BATTLESCARRED
NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death
Click Here to Manage Email Alerts
Trial assessed hormone-guided treatment strategy for treatment of chronic HF compared with intensive clinical management and usual care.
Design: randomized
Patients: 364
Centers: single
Country: New Zealand
RESULTS: One-year mortality was less in both the NT-proBNP group (9.1%) and the intensive clinical management group (9.1%) vs. the usual care group (18.9%, P=.03). In patents <75 years of age, NT-proBNP-guided therapy was associated with reduced three-year mortality (15.5%) when compared with either intensive clinical management (30.9%, P=.048) or usual care (31.3%, P=.021). Overall hospitalizations for HF did not differ between the study groups, and there were no differences in the secondary outcomes of death plus hospital admission from any CV event or total hospital admissions.
Published in: J Am Coll Cardiol. 2009;55:53-60.
Click here to read more about the BATTLESCARRED trial.